Hanx Bio repurchases 0.04 million H shares at up to HKD 27.98, expands treasury stock to 1.04 million

Bulletin Express06-05

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“Hanx Bio”) disclosed a Next Day Disclosure Return showing that on 5 June 2026 it repurchased 39,100 H shares on the Hong Kong Stock Exchange.

The on-market buy-back was executed within a price range of HKD 26.52 to HKD 27.98 per share, with a volume-weighted average cost of HKD 27.23. Total consideration amounted to HKD 1.06 million.

Following the transaction: • Issued shares (excluding treasury shares) fell from 135.21 million to 135.17 million, a decrease of 0.03%. • Treasury shares rose from 1.01 million to 1.04 million. • Total issued share capital remained unchanged at 136.22 million, as the repurchased shares are being held in treasury rather than cancelled.

Under the repurchase mandate granted on 12 February 2026, Hanx Bio is authorised to buy back up to 13.62 million shares. Cumulative repurchases now stand at 1.04 million shares, representing 0.77% of the company’s issued shares on the mandate date and roughly 7.66% of the authorised limit.

In accordance with Hong Kong listing rules, the company is subject to a moratorium on new share issues or sales of treasury shares until 5 July 2026. The board confirmed that all buy-backs were conducted within regulatory guidelines.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125200380?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125200380","market":"us","top_or_hot":-1,"title":"Hanx Bio repurchases 0.04 million H shares at up to HKD 27.98, expands treasury stock to 1.04 million","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“Hanx Bio”) disclosed a Next Day Disclosure Return showing that on 5 June 2026 it repurchased 39,100 H shares on the Hong Kong Stock Exchange.</p>\n<p>The on-market buy-back was executed within a price range of HKD 26.52 to HKD 27.98 per share, with a volume-weighted average cost of HKD 27.23. Total consideration amounted to HKD 1.06 million.</p>\n<p>Following the transaction:  \n• Issued shares (excluding treasury shares) fell from 135.21 million to 135.17 million, a decrease of 0.03%.  \n• Treasury shares rose from 1.01 million to 1.04 million.  \n• Total issued share capital remained unchanged at 136.22 million, as the repurchased shares are being held in treasury rather than cancelled.</p>\n<p>Under the repurchase mandate granted on 12 February 2026, Hanx Bio is authorised to buy back up to 13.62 million shares. Cumulative repurchases now stand at 1.04 million shares, representing 0.77% of the company’s issued shares on the mandate date and roughly 7.66% of the authorised limit.</p>\n<p>In accordance with Hong Kong listing rules, the company is subject to a moratorium on new share issues or sales of treasury shares until 5 July 2026. The board confirmed that all buy-backs were conducted within regulatory guidelines.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Bio repurchases 0.04 million H shares at up to HKD 27.98, expands treasury stock to 1.04 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Bio repurchases 0.04 million H shares at up to HKD 27.98, expands treasury stock to 1.04 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-05 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“Hanx Bio”) disclosed a Next Day Disclosure Return showing that on 5 June 2026 it repurchased 39,100 H shares on the Hong Kong Stock Exchange.</p>\n<p>The on-market buy-back was executed within a price range of HKD 26.52 to HKD 27.98 per share, with a volume-weighted average cost of HKD 27.23. Total consideration amounted to HKD 1.06 million.</p>\n<p>Following the transaction:  \n• Issued shares (excluding treasury shares) fell from 135.21 million to 135.17 million, a decrease of 0.03%.  \n• Treasury shares rose from 1.01 million to 1.04 million.  \n• Total issued share capital remained unchanged at 136.22 million, as the repurchased shares are being held in treasury rather than cancelled.</p>\n<p>Under the repurchase mandate granted on 12 February 2026, Hanx Bio is authorised to buy back up to 13.62 million shares. Cumulative repurchases now stand at 1.04 million shares, representing 0.77% of the company’s issued shares on the mandate date and roughly 7.66% of the authorised limit.</p>\n<p>In accordance with Hong Kong listing rules, the company is subject to a moratorium on new share issues or sales of treasury shares until 5 July 2026. The board confirmed that all buy-backs were conducted within regulatory guidelines.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1125200380","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125200380","pubTimestamp":1780657656,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“Hanx Bio”) disclosed a Next Day Disclosure Return showing that on 5 June 2026 it repurchased 39,100 H shares on the Hong Kong Stock Exchange. The on-market...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"Hanx Bio以最高27.98港元回购4万股H股，库存股扩大至104万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“Hanx Bio”) disclosed a Next Day Disclosure Return showing that on 5 June 2026 it repurchased 39,100 H shares on the Hong Kong Stock Exchange.\nThe on-market buy-back was executed within a price range of HKD 26.52 to HKD 27.98 per share, with a volume-weighted average cost of HKD 27.23. Total consideration amounted to HKD 1.06 million.\nFollowing the transaction:  \n• Issued shares (excluding treasury shares) fell from 135.21 million to 135.17 million, a decrease of 0.03%.  \n• Treasury shares rose from 1.01 million to 1.04 million.  \n• Total issued share capital remained unchanged at 136.22 million, as the repurchased shares are being held in treasury rather than cancelled.\nUnder the repurchase mandate granted on 12 February 2026, Hanx Bio is authorised to buy back up to 13.62 million shares. Cumulative repurchases now stand at 1.04 million shares, representing 0.77% of the company’s issued shares on the mandate date and roughly 7.66% of the authorised limit.\nIn accordance with Hong Kong listing rules, the company is subject to a moratorium on new share issues or sales of treasury shares until 5 July 2026. The board confirmed that all buy-backs were conducted within regulatory guidelines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125200380","isCrawlerRequest":true}